144 related articles for article (PubMed ID: 37138965)
1. XPERT
Borges PCC; Spencer HB; Barbosa C; Costa V; Furtado A; Leal MC; Lopes C; Ferreira D; Carvalho AL; Dos-Santos-Silva I; Santos LL
Ecancermedicalscience; 2023; 17():1530. PubMed ID: 37138965
[TBL] [Abstract][Full Text] [Related]
2. Use of the Xpert Breast Cancer STRAT4 for Biomarker Evaluation in Tissue Processed in a Developing Country.
Mugabe M; Ho KE; Ruhangaza D; Milner D; Rugwizangoga B; Chu VC; Wu NC; Rizo A; Weidler JM; Wong W; Bates M; Brock JE
Am J Clin Pathol; 2021 Oct; 156(5):766-776. PubMed ID: 34050358
[TBL] [Abstract][Full Text] [Related]
3. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
[TBL] [Abstract][Full Text] [Related]
4. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Xpert Breast Cancer STRAT 4 Assay on the GeneXpert instrument to Assess Hormone Receptor, Ki67, and HER2 Gene Expression Status in Breast Cancer Tissue Samples.
Sewanywa L; Hale M; Michelow P; Mayne E; Wiggill T
Appl Immunohistochem Mol Morphol; 2023 Oct; 31(9):613-620. PubMed ID: 37800656
[TBL] [Abstract][Full Text] [Related]
6. Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens.
Janeva S; Parris TZ; Nasic S; De Lara S; Larsson K; Audisio RA; Olofsson Bagge R; Kovács A
BMC Cancer; 2021 Apr; 21(1):439. PubMed ID: 33879115
[TBL] [Abstract][Full Text] [Related]
7. Reproducibility of mRNA-Based Testing of
Erber R; Hartmann A; Fasching PA; Ruebner M; Stöhr R; Beckmann MW; Zentgraf M; Popp V; Weidler J; Simon I; Becker S; Huebner H; Fischer J; Guerini Rocco E; Viale G; Cayre A; Penault-Llorca F; Caniego Casas T; Pérez-Miés B; Palacios J; Jank P; Denkert C; Khoury L; Mairinger T; Ferrazzi F
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572945
[TBL] [Abstract][Full Text] [Related]
8. Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer.
Gupta S; Mani NR; Carvajal-Hausdorf DE; Bossuyt V; Ho K; Weidler J; Wong W; Rhees B; Bates M; Rimm DL
Lab Invest; 2018 Aug; 98(8):1076-1083. PubMed ID: 29858579
[TBL] [Abstract][Full Text] [Related]
9. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of
Carretero-Barrio I; Caniego-Casas T; Rosas M; Sánchez MC; Martínez-Jáñez N; Chiva M; Sarrió D; Moreno-Bueno G; Palacios J; Pérez-Mies B
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980575
[TBL] [Abstract][Full Text] [Related]
11. Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
Badr NM; Zaakouk M; Zhang Q; Kearns D; Kong A; Shaaban AM
Histopathology; 2024 Apr; ():. PubMed ID: 38651302
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry versus PCR Technology for Molecular Subtyping of Breast Cancer: Multicentered Expereinces from Addis Ababa, Ethiopia.
Oma D; Teklemariam M; Seifu D; Desalegn Z; Anberbir E; Abebe T; Mequannent S; Tebeje S; Labisso WL
J Cancer Prev; 2023 Jun; 28(2):64-74. PubMed ID: 37434799
[TBL] [Abstract][Full Text] [Related]
13. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.
Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD
Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323
[TBL] [Abstract][Full Text] [Related]
14. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
Laible M; Schlombs K; Kaiser K; Veltrup E; Herlein S; Lakis S; Stöhr R; Eidt S; Hartmann A; Wirtz RM; Sahin U
BMC Cancer; 2016 Jul; 16():398. PubMed ID: 27389414
[TBL] [Abstract][Full Text] [Related]
15. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer molecular diagnostics in Rwanda: a cost-minimization study of immunohistochemistry versus a novel GeneXpert
Erfani P; Gaga E; Hakizimana E; Kayitare E; Mugunga JC; Shyirambere C; Milner DA; Shulman LN; Ruhangaza D; Fadelu T
Bull World Health Organ; 2023 Jan; 101(1):10-19. PubMed ID: 36593782
[TBL] [Abstract][Full Text] [Related]
17. ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
Park MM; Ebel JJ; Zhao W; Zynger DL
Breast J; 2014; 20(1):37-45. PubMed ID: 24261318
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.
Wang HY; Park S; Kim S; Ahn S; Lee D; Kim S; Jung D; Park KH; Lee H
Int J Clin Exp Pathol; 2014; 7(9):5792-800. PubMed ID: 25337220
[TBL] [Abstract][Full Text] [Related]
19. Effect of EDTA decalcification on estrogen receptor and progesterone receptor immunohistochemistry and HER2/neu fluorescence in situ hybridization in breast carcinoma.
Washburn E; Tang X; Caruso C; Walls M; Han B
Hum Pathol; 2021 Nov; 117():108-114. PubMed ID: 34461131
[TBL] [Abstract][Full Text] [Related]
20. An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.
Wesseling J; Tinterri C; Sapino A; Zanconati F; Lutke-Holzik M; Nguyen B; Deck KB; Querzoli P; Perin T; Giardina C; Seitz G; Guinebretière JM; Barone J; Dekker L; de Snoo F; Stork-Sloots L; Roepman P; Watanabe T; Cusumano P
Virchows Arch; 2016 Sep; 469(3):297-304. PubMed ID: 27377889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
